North America Circulating Tumor Cells Ctc Liquid Biopsy Market Analysis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TECHNOLOGY LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 REGULATIONS: NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

5.1 ROLE OF FDA

5.2 ROLE OF CDC AND HCFA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 HIGH PREVALENCE OF CANCER

6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY

6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER

6.1.4 RISE IN FDA APPROVAL

6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY

6.2 RESTRAINTS

6.2.1 DOWNSIDES OF LIQUID BIOPSY

6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS

6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME

6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES

6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES

6.4 CHALLENGES

6.4.1 SHORTAGE OF SKILLED PERSONNEL

6.4.2 LACK OF ACCESSIBILITY

7 COVID-19 IMPACT ON NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY

7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19

7.5 CONCLUSION:

8 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY

8.1 OVERVIEW

8.2 CTC DETECTION METHODS

8.3 CTC ENRICHMENT METHODS

8.4 EX VIVO POSITIVE SELECTION

8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES

8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY

8.7 XENOTRANSPLANTATION MODELS

8.8 MICROCHIPS

8.9 SINGLE SPIRAL MICROCHANNEL

8.1 NEGATIVE SELECTION

8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES

9 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 CANCER STEM CELL RESEARCH

9.3 MULTIPLE CHROMOSOME ABNORMALITIES

9.4 OTHERS

10 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER

10.1 OVERVIEW

10.2 RESEARCH & ACADEMIC INSTITUTES

10.3 REFERENCE LABORATORIES

10.4 HOSPITALS AND PHYSICIAN LABORATORIES

11 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION

11.1 NORTH AMERICA

11.1.1 U.S.

11.1.2 CANADA

11.1.3 MEXICO

12 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 GUARDANT HEALTH

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC)

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 FOUNDATION MEDICINE, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 COMPANY SHARE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENTS

14.4 ILLUMINA, INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 NATERA, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 BIO-RAD LABORATORIES, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 QIAGEN

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 THERMO FISHER SCIENTIFIC INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 BIOCEPT, INC.

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.9.4 RECENT DEVELOPMENT

14.1 BIOLIDICS LIMITED

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 EXACT SCIENCES CORPORATION

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION)

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENTS

14.13 F. HOFFMANN-LA ROCHE LTD

14.13.1 COMPANY SNAPSHOT

14.13.2 RECENT FINANCIALS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENTS

14.14 IMMUCOR

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 INIVATA LTD

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 LUCENCE HEALTH, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

14.17 LUNGLIFE AI, INC.

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 MDXHEALTH

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 MENARINI SILICON BIOSYSTEMS

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENTS

14.2 MYRIAD GENETICS, INC.

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

14.21 VORTEX BIOSCIENCES

14.21.1 COMPANY SNAPSHOT

14.21.2 PRODUCT PORTFOLIO

14.21.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS